Executive summary
US Patent 11,998,639 covers a narrow set of immediate-release (IR) oral solid formulations of (R)-2-amino-3-phenylpropyl carbamate (base) as a pharmaceutically acceptable salt, specifically exemplified by the hydrochloride, formulated with hydroxypropyl cellulose (HPC) and magnesium stearate, engineered to deliver rapid dissolution (≥85% release in <15 minutes) with substantially identical dissolution at pH 1.2/4.5/6.8, and explicitly excluding disintegrants. Independent protection is split across (i) a composition/formulation claim (claim 1) and (ii) therapeutic use methods (claim 16 and dependent claims) that include multiple CNS indications plus smoking cessation.
Below is a claim-scope map and a litigation- and entry-relevant patent landscape assessment for the US claims as provided.
Scope and claims of US Patent 11,998,639: what is protected and what is excluded?
What is the claimed dosage form and composition architecture? (Claim 1)
Claim 1 is limited to a solid pharmaceutical formulation for oral delivery of a specific drug entity:
-
Drug substance: pharmaceutically acceptable salt of (R)-2-amino-3-phenylpropyl carbamate
- Salt content: about 90–98% by weight of the formulation
- Dependent claim 6 narrows salt to (R)-2-amino-3-phenylpropyl carbamate hydrochloride.
-
Matrix/solid excipient: hydroxypropyl cellulose (HPC)
- Level: 1–5% by weight (further narrowed in claims 12 and 14: “about 1–3%” and “about 2%”).
-
Lubricant: magnesium stearate
- Level: 0.1–2% by weight (further narrowed in claims 13 and 15: “about 0.1–1.0%” and “about 0.5%”).
-
Disintegrant exclusion: formulation does not comprise a disintegrant (hard negative limitation).
-
Dissolution performance constraints:
- Release: at least 85% of the salt is released within <15 minutes after administration.
- pH comparability: exhibits substantially identical dissolution rates at pH 1.2, pH 4.5, and pH 6.8.
-
No additional excipients are expressly permitted in claim 1 other than the listed components; practical scope depends on whether claim construction permits “incidental” or “trace” materials that do not meet the “comprising” boundary. In US practice, “comprising” typically allows additional components, but the negative limitation “does not comprise a disintegrant” remains binding.
What does the patent cover in claim breadth terms? (Coverage boundaries)
Core protection is centered on a high drug-load IR solid where the drug salt is dominant by weight (90–98%), with a relatively small percentage of HPC and magnesium stearate, plus a performance profile tied to dissolution/release kinetics.
The claims therefore tend to be most vulnerable to design-arounds that change at least one of these pillars:
- remove/replace HPC (or move outside the 1–5% range),
- remove/replace magnesium stearate (or move outside 0.1–2%),
- include a disintegrant (explicitly prohibited),
- change salt identity (if claim scope is contested beyond “pharmaceutically acceptable salt,” dependent claim 6 narrows),
- or alter dissolution behavior (miss the ≥85% in <15 minutes or the “substantially identical” pH dissolution requirement).
How are tablet forms handled? (Claims 2 and 17)
- Claim 2: formulation of claim 1 is a tablet.
- Claim 17: method of claim 16 uses a tablet formulation.
These restrict enforceable products to solid oral tablets when the dependent claims are asserted, but claim 1 remains broader than tablets because it only requires a “solid pharmaceutical formulation for oral delivery.”
What are the performance “hard stops”? (Claims 1 and 3)
- Claim 1: ≥85% release within <15 minutes.
- Claim 3: ≥95% release within <15 minutes.
Claim 3 creates a second performance tier. A generic that meets claim 1 but not claim 3 could still infringe claim 1 if the other elements are met.
What excipient refinements narrow the claim set? (Claims 12–15)
-
HPC:
- Claim 12: about 1–3%
- Claim 14: about 2%
-
Magnesium stearate:
- Claim 13: about 0.1–1.0%
- Claim 15: about 0.5%
These dependent limits matter for freedom-to-operate because they create specific “target boxes” for formulation matching. If an entrant chooses a level outside the broad independent range, it may exit claim 1 entirely; if it stays within claim 1 but chooses outside dependent boxes, infringement becomes less likely on those dependents while still possible on claim 1.
How does coating play into protection? (Claims 4 and 5)
- Claim 4: formulation further comprises a coating.
- Claim 5: coating is a color overcoat.
If asserted, these dependents can cover specific finishing steps. However, the main dissolution profile limitation in claim 1 could be impacted by coating type and thickness; coating design therefore interacts with infringement risk.
US Patent 11,998,639 method-of-use scope: which indications and endpoints are claimed (claim 16)?
What conditions are covered for oral administration? (Claim 16)
Claim 16 is a broad method of treating multiple disorders and promoting smoking cessation. It requires administering the claimed formulation and ties treatment to the same formulation constraints from claim 1. Indications listed:
- Narcolepsy
- Cataplexy
- Excessive daytime sleepiness
- Drug addiction
- Sexual dysfunction
- Fatigue
- Fibromyalgia
- Attention deficit/hyperactivity disorder (ADHD)
- Restless legs syndrome (RLS)
- Depression
- Bipolar disorder
- Obesity
- Promoting smoking cessation
Because claim 16 is method-of-use, an infringing product is typically the same formulation used for any of these indications. Even if a generic product is sold for one non-covered indication, method-of-use infringement risk turns on prescribing and promotional conduct in the US.
Dependent method claims
- Claim 17: tablet formulation.
- Claim 18: salt is specifically hydrochloride.
- Claim 19: about 30–300 mg salt per dose.
This dose band creates another boundary for entry strategy: a dose outside 30–300 mg may avoid dependents 18/19 while still potentially infringing claim 16 depending on claim construction and remaining limitations.
How do the claims translate into infringement and design-around risk?
What are the highest-leverage claim elements for a generic or competitor?
The enforcement “tripwires” are:
- Drug salt identity and loading
- If the salt used is not “pharmaceutically acceptable” for the same drug or the fraction falls outside 90–98% by weight, claim 1 is a poor match.
- HPC presence and range (1–5% by weight)
- Removing HPC or moving outside the range is a typical design-around vector.
- Magnesium stearate presence and range (0.1–2% by weight)
- Replacement lubricants or outside-range levels can help avoid literal infringement.
- No disintegrant
- Formulation strategies that include disintegrants can exit claim scope directly on the negative limitation.
- Dissolution/release performance
- The formulation must release ≥85% in <15 minutes and maintain “substantially identical” dissolution at pH 1.2/4.5/6.8.
- These performance metrics are often the hardest to “guess” and can become central to ANDA bioequivalence and lab tests.
How strong is the claim stance based on the provided language alone?
- Formulation claim strength: moderate to high for products that resemble the described high drug-load IR composition using HPC + magnesium stearate and achieving the specified dissolution profile.
- Claim vulnerability: reduced for entrants that use alternative excipient systems (including disintegrants), alternative polymer binders, or different salt forms/dose structures that change dissolution behavior.
What formulations are protected by US Patent 11,998,639? (Matrix of claim limits)
| Claim cluster |
Protected element |
Specific numerical boundaries in provided claims |
| Core composition |
Salt of (R)-2-amino-3-phenylpropyl carbamate |
90–98% w/w |
| Core composition |
Hydroxypropyl cellulose |
1–5% w/w |
| Core composition |
Magnesium stearate |
0.1–2% w/w |
| Performance |
Rapid release |
≥85% released <15 min (claim 1) |
| Performance |
pH dissolution similarity |
“Substantially identical” at pH 1.2, 4.5, 6.8 |
| Exclusion |
Disintegrant |
No disintegrant |
| Tablet |
Dosage form |
Tablet (claim 2; method claim 17) |
| Performance tier |
Higher dissolution |
≥95% <15 min (claim 3) |
| Dose |
Salt per unit |
~300 mg, 150 mg, 75 mg, 37.5 mg (claims 7–10) |
| Dose total weight |
Total tablet weight |
30–300 mg (claim 11) |
| Coating |
Additional element |
Coating (claim 4) and color overcoat (claim 5) |
| Salt identity (narrow) |
Hydrochloride specifically |
Hydrochloride (claim 6; method claim 18) |
This grid shows the patent’s practical coverage: it is not a generic “use my drug” patent. It is a formulation-and-performance patent with a method overlay.
What patent landscape questions does US 11,998,639 raise for exclusivity, Orange Book status, and generic entry?
When does US 11,998,639 lose exclusivity?
No patent expiration date is derivable from the claim text alone. US exclusivity timing depends on:
- the patent’s filing/priority dates,
- patent term adjustments,
- maintenance payments,
- and whether the patent is listed for a specific FDA product.
Because the underlying filing and status are not included, a specific calendar date cannot be stated from the provided information.
Is it listed in the Orange Book for a specific NDA?
Orange Book listing status requires the patent’s application/NDA/BLA linkage or the patent-to-product listing. That linkage is not provided. The claim text alone does not identify the FDA reference product(s).
Does the patent have biosimilar relevance?
This patent is a small-molecule formulation claim (carbamate salt formulation and tablet excipients), not a biologic. Biosimilar pathways are not applicable based on the subject matter described.
How does this patent compare with typical IR formulation patents in US practice?
What makes it comparatively narrow versus broad?
Compared with wide IR patents that may cover multiple polymers, disintegrants, and ranges, US 11,998,639 is constrained by:
- a very high salt loading (90–98%),
- specific excipient identities (HPC + magnesium stearate),
- an explicit disintegrant exclusion,
- and specific dissolution performance metrics across multiple pH points.
These constraints reduce literal infringement surface area, but they also create clear constraints that can be tested and argued.
Is the dissolution requirement likely to be enforceable as a claim limitation?
Yes, because it is written as part of the formulation’s properties in the claim. For enforcement, the patentee can test dissolution under relevant conditions; for defense, the accused product’s dissolution profile can be compared to the claim language. The pH comparability element can become a key factual dispute.
Key litigation and challenge pathways relevant to this claim set (Paragraph IV, IPR, design-around testing)
What generic entry risks exist if an ANDA targets the same reference product?
Risk is highest if an ANDA applicant:
- uses a hydrochloride (or another pharmaceutically acceptable salt) as the same drug form,
- formulates with HPC at 1–5% w/w and uses magnesium stearate at 0.1–2% w/w,
- avoids disintegrants,
- and achieves rapid release with substantially identical dissolution at pH 1.2/4.5/6.8.
Risk is lower if the ANDA:
- includes a disintegrant,
- changes the polymer system away from HPC,
- replaces magnesium stearate with another lubricant at meaningfully different levels,
- or intentionally changes dissolution across the pH points.
How could a challenger attack scope without reading on the claims?
Common approaches with this type of claim structure:
- argue non-infringement due to excipient identity/range and “does not comprise a disintegrant,”
- argue non-infringement due to dissolution outcomes at the specified pH,
- argue invalidity via obviousness or lack of novelty against IR formulation prior art, or indefiniteness if “substantially identical” is contested.
The specific patentability record cannot be analyzed from claim text alone.
Key takeaways
- US 11,998,639 protects a high drug-load IR oral solid of (R)-2-amino-3-phenylpropyl carbamate as a pharmaceutically acceptable salt (with hydrochloride specifically claimed in dependent claims), using HPC (1–5% w/w) and magnesium stearate (0.1–2% w/w), with no disintegrant and rapid dissolution (≥85% in <15 min, optionally ≥95%).
- The claims add enforceability levers through pH dissolution similarity at pH 1.2/4.5/6.8 and multiple dose embodiments.
- Method-of-use claim 16 covers treatment of a wide list of CNS/metabolic indications and smoking cessation, but it still requires use of the claimed formulation.
- For entry planning, the most actionable infringement determinants are excipient selection/ranges, disintegrant avoidance, salt form/loading, and measured dissolution profiles across the three pH conditions.
FAQs
1) What excipients are required to infringe US 11,998,639 claim 1?
HPC (1–5% w/w), magnesium stearate (0.1–2% w/w), and the salt of (R)-2-amino-3-phenylpropyl carbamate as the dominant component (90–98% w/w), with the formulation explicitly not comprising a disintegrant.
2) Does the patent cover hydrochloride specifically?
Yes. Dependent claims specify (R)-2-amino-3-phenylpropyl carbamate hydrochloride (claim 6 for composition; claim 18 for method).
3) What dissolution target does the patent require?
Claim 1 requires ≥85% released within <15 minutes; claim 3 requires ≥95% within <15 minutes.
4) Is pH-dependent dissolution part of the claim scope?
Yes. Claim 1 requires “substantially identical dissolution rates” at pH 1.2, 4.5, and 6.8.
5) Which indications are covered under the method-of-use claim?
Narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, sexual dysfunction, fatigue, fibromyalgia, ADHD, restless legs syndrome, depression, bipolar disorder, obesity, and smoking cessation.
References (APA)
- US Patent 11,998,639, claims 1–19 (provided in prompt).
